Table 2 Treatment of patients with COVID-19
Characteristics | All patients N=300 | GI group N=104 | Non-GI group N=196 | P value | |||
|---|---|---|---|---|---|---|---|
Treatment, n (%) | |||||||
Colchicine | 26 | (8.7) | 10 | (9.6) | 16 | (8.2) | 0.67 |
Antiviral | 78 | (26.0) | 32 | (30.8) | 46 | (23.5) | 0.2 |
HQ | 69 | (23.0) | 31 | (29.8) | 38 | (19.4) | 0.04* |
Remdesivir | 13 | (4.3) | 3 | (2.9) | 10 | (5.1) | 0.41 |
Anti-IL6 | 10 | (3.3) | 5 | (4.8) | 5 | (2.6) | 0.32 |
Macrolides | 180 | (60.0) | 59 | (56.7) | 121 | (61.7) | 0.38 |
Cephalosporines | 155 | (51.7) | 48 | (46.2) | 107 | (54.6) | 0.21 |
Penicillin | 2 | (0.7) | 2 | (1.9) | 0 | (0.0) | 0.05 |
Quinolones | 42 | (14.0) | 18 | (17.3) | 24 | (12.2) | 0.22 |
Carbapenems | 155 | (51.7) | 50 | (48.1) | 105 | (53.6) | 0.37 |
Linezolid | 138 | (46.0) | 47 | (45.2) | 91 | (46.4) | 0.83 |
Acyclovir | 2 | (0.7) | 1 | (1.0) | 1 | (0.5) | 0.65 |
Antifungal | 10 | (3.3) | 4 | (3.8) | 6 | (3.1) | 0.72 |
Racecadotril | 1 | (0.3) | 1 | (1.0) | 0 | (0.0) | 0.17 |
Rifaximin | 11 | (3.7) | 10 | (9.6) | 1 | (0.5) | 0.000** |
Metronidazole | 21 | (7.0) | 21 | (20.2) | 0 | (0.0) | 0.000** |
Nanazoxid | 22 | (7.3) | 22 | (21.2) | 0 | (0.0) | 0.000** |